Kenneth Barr
About Kenneth Barr
Kenneth Barr is the Senior Vice President of Discovery Services at Syngene, with a Ph.D. in Synthetic Organic/Organometallic Chemistry from MIT and extensive experience in drug discovery.
Title: Senior Vice President – Discovery Services
Kenneth Barr holds the position of Senior Vice President – Discovery Services at Syngene. In this role, he is responsible for overseeing and guiding various aspects of discovery services, from strategic planning to operational execution. His work involves providing leadership to ensure that discovery projects meet their objectives and advance from concept through to delivery efficiently.
Education and Expertise in Synthetic Organic Chemistry
Kenneth Barr has a strong academic background with a Ph.D. in Synthetic Organic/Organometallic Chemistry earned from the esteemed Massachusetts Institute of Technology (MIT). This foundation has equipped him with a deep understanding of complex chemical processes, which he applies in his professional roles. Furthermore, he completed postdoctoral studies in natural product synthesis at the University of Texas, adding another layer of specialization to his expertise.
Background in Drug Discovery
Kenneth Barr has accumulated over twenty years of experience in drug discovery, focusing on both small molecules and biologics. He has worked in various capacities to develop and refine drugs, contributing significantly to advancements in the field. His extensive experience spans multiple organizations and areas of drug development.
Previous Roles at Leading Pharmaceutical Companies
Prior to his current role at Syngene, Kenneth Barr has been associated with several renowned pharmaceutical companies. He has worked at Merck, Amplyx Pharmaceuticals Inc., and Sunesis in various capacities, contributing to their respective drug discovery and development projects. His experience at these companies has helped shape his expertise and approach in the field.
Leadership Role at FORMA Therapeutics
Before joining Syngene, Kenneth Barr served as the Head of R&D Strategic Global Operations at FORMA Therapeutics. In this capacity, he was responsible for overseeing research and development operations on a global scale, ensuring that strategic goals were met and resources were effectively utilized. His leadership at FORMA Therapeutics highlights his capability to manage complex, large-scale R&D initiatives.